Profesorskie Centrum Medyczne Sp. z o.o.
- Address
- Ul. Warszawska 20, 80-180 Gdansk, Poland
Retinal Vascular Disorders
The ophthalmology department at Profesorskie Centrum Medyczne Sp. z o.o. conducts trials aimed at improving visual acuity for patients with sight‑threatening retinal conditions by testing new anti‑VEGF alternatives and novel injection therapies.
- Diabetic Macular Edema
- Neovascular age‑related macular degeneration (nAMD)
Ongoing research seeks to provide safer and more effective options for individuals at risk of vision loss due to retinal vascular disease.
Thyroid Eye Disease (TED)
Clinical studies focus on moderate‑to‑severe active thyroid eye disease, evaluating innovative biologics and small‑molecule agents to reduce proptosis and improve ocular comfort.
- Moderate-to-Severe Active Thyroid Eye Disease
- Chronic Thyroid Eye Disease
The Gdańsk site offers open‑label access for participants who have not responded to existing therapies, advancing treatment possibilities for this disabling condition.
Uveitis and Inflammatory Eye Conditions
Trials investigate emerging immunomodulators for non‑infectious uveitis, targeting intermediate, posterior, and pan‑uveitis to control inflammation and preserve sight.
- Active non‑infectious uveitis
- Intermediate uveitis
- Posterior uveitis
- Panuveitis
Researchers assess safety and efficacy of these agents to offer new therapeutic pathways for patients with chronic ocular inflammation.
Acquired Blepharoptosis
A focused study evaluates topical treatments designed to correct acquired blepharoptosis, aiming for rapid functional improvement of eyelid position.
- Acquired Blepharoptosis
The investigation explores convenient eye‑drop formulations that could replace more invasive surgical options.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Eyebiotech Limited1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eyebiotech Limited3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Profesorskie Centrum Medyczne Sp. z o.o.
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Intravitreal EYE103 Versus Ranibizumab in Diabetic Macular Edema: A Randomized, Double-Masked, Phase 2/3 Study | Eyebiotech Limited | Phase IV | Not Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorescein Sodium | 3 | Unknown | 2024-11-22 | 2025-10-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.